HUTCHMED (NASDAQ:HCM) Stock Crosses Below 50 Day Moving Average – Here’s What Happened

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s share price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $14.69 and traded as low as $14.32. HUTCHMED shares last traded at $14.33, with a volume of 19,957 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Finally, Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.88.

HUTCHMED Stock Down 2.6%

The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51. The firm’s 50-day simple moving average is $14.69 and its two-hundred day simple moving average is $15.05.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. State Street Corp increased its stake in shares of HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after buying an additional 3,801 shares during the period. Renaissance Technologies LLC increased its position in HUTCHMED by 3.0% in the fourth quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after purchasing an additional 3,900 shares during the period. Dimensional Fund Advisors LP raised its holdings in HUTCHMED by 157.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock worth $746,000 after purchasing an additional 34,248 shares during the last quarter. M&G PLC lifted its position in HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares during the period. Finally, XY Capital Ltd boosted its stake in shares of HUTCHMED by 9.2% in the 4th quarter. XY Capital Ltd now owns 57,610 shares of the company’s stock valued at $768,000 after purchasing an additional 4,853 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.